{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:47:18Z","timestamp":1792698438444,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.lfs.2024.122641","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T18:48:07Z","timestamp":1713206887000},"page":"122641","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction"],"prefix":"10.1016","volume":"346","author":[{"given":"Taku","family":"Nakai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Saigusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Fukuuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seizo","family":"Koshiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.lfs.2024.122641_bb0005","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1182\/blood-2007-10-115857","article-title":"Repression via the GATA box is essential for tissue-specific erythropoietin gene expression","volume":"111","author":"Obara","year":"2008","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.lfs.2024.122641_bb0010","doi-asserted-by":"crossref","first-page":"e25839","DOI":"10.1371\/journal.pone.0025839","article-title":"Isolation and characterization of renal erythropoietin-producing cells from genetically produced anemia mice","volume":"6","author":"Pan","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.lfs.2024.122641_bb0015","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1620\/tjem.235.233","article-title":"Erythropoietin gene expression: developmental-stage specificity, cell-type specificity, and hypoxia inducibility","volume":"235","author":"Suzuki","year":"2015","journal-title":"Tohoku J. Exp. Med."},{"issue":"15","key":"10.1016\/j.lfs.2024.122641_bb0020","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1128\/MCB.00161-15","article-title":"Hypoxia signaling cascade for erythropoietin production in hepatocytes","volume":"35","author":"Tojo","year":"2015","journal-title":"Mol. Cell. Biol."},{"issue":"22","key":"10.1016\/j.lfs.2024.122641_bb0025","doi-asserted-by":"crossref","first-page":"7972","DOI":"10.1073\/pnas.84.22.7972","article-title":"The regulated expression of erythropoietin by two human hepatoma cell lines","volume":"84","author":"Goldberg","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.lfs.2024.122641_bb0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.semnephrol.2006.06.001","article-title":"Pathogenesis of renal anemia","volume":"26","author":"Nangaku","year":"2006","journal-title":"Semin. Nephrol."},{"issue":"9","key":"10.1016\/j.lfs.2024.122641_bb0035","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.3324\/haematol.2015.140814","article-title":"Efficacy estimation of erythropoiesis-stimulating agents using erythropoietin-deficient anemic mice","volume":"101","author":"Suzuki","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.lfs.2024.122641_bb0040","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/ki.2011.179","article-title":"Pattern of resistance to erythropoietin-stimulating agents in chronic kidney disease","volume":"80","author":"Bamgbola","year":"2011","journal-title":"Kidney Int."},{"issue":"4","key":"10.1016\/j.lfs.2024.122641_bb0045","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ki.2009.460","article-title":"Hypoxia-inducible factor-2alpha-expressing interstitial fibroblasts are the only renal cells that express erythropoietin under hypoxia-inducible factor stabilization","volume":"77","author":"Paliege","year":"2010","journal-title":"Kidney Int."},{"issue":"8","key":"10.1016\/j.lfs.2024.122641_bb0050","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1113\/jphysiol.2013.251470","article-title":"Oxygen sensing and hypoxia signalling pathways in animals: the implications of physiology for cancer","volume":"591","author":"Ratcliffe","year":"2013","journal-title":"J. Physiol."},{"key":"10.1016\/j.lfs.2024.122641_bb0055","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1146\/annurev-pharmtox-010818-021637","article-title":"Pharmacologic targeting of hypoxia-inducible factors","volume":"59","author":"Semenza","year":"2019","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.lfs.2024.122641_bb0060","first-page":"176","article-title":"Hydroxylation of HIF-1: oxygen sensing at the molecular level","volume":"19","author":"Semenza","year":"2004","journal-title":"Physiology (Bethesda)"},{"issue":"2","key":"10.1016\/j.lfs.2024.122641_bb0065","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1681\/ASN.2014121184","article-title":"Erythropoietin synthesis in renal myofibroblasts is restored by activation of hypoxia signaling","volume":"27","author":"Souma","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"5","key":"10.1016\/j.lfs.2024.122641_bb0070","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s40265-019-01077-1","article-title":"Roxadustat: first global approval","volume":"79","author":"Dhillon","year":"2019","journal-title":"Drugs"},{"issue":"13","key":"10.1016\/j.lfs.2024.122641_bb0075","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s40265-020-01383-z","article-title":"Vadadustat: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.lfs.2024.122641_bb0080","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40265-020-01444-3","article-title":"Enarodustat: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"issue":"14","key":"10.1016\/j.lfs.2024.122641_bb0085","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s40265-020-01384-y","article-title":"Daprodustat: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.lfs.2024.122641_bb0090","doi-asserted-by":"crossref","first-page":"1131516","DOI":"10.3389\/fendo.2023.1131516","article-title":"Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: a network meta-analysis","volume":"14","author":"Yang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"10.1016\/j.lfs.2024.122641_bb0095","doi-asserted-by":"crossref","first-page":"e13826","DOI":"10.1111\/apha.13826","article-title":"EPO synthesis induced by HIF-PHD inhibition is dependent on myofibroblast transdifferentiation and colocalizes with non-injured nephron segments in murine kidney fibrosis","volume":"235","author":"Kobayashi","year":"2022","journal-title":"Acta Physiol (Oxford)"},{"key":"10.1016\/j.lfs.2024.122641_bb0100","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.3389\/fgene.2019.01134","article-title":"Alteration of the DNA methylation signature of renal erythropoietin-producing cells governs the sensitivity to drugs targeting the hypoxia-response pathway in kidney disease progression","volume":"10","author":"Sato","year":"2019","journal-title":"Front. Genet."},{"issue":"3","key":"10.1016\/j.lfs.2024.122641_bb0105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000492181","article-title":"Novel compound induces erythropoietin secretion through liver effects in chronic kidney disease patients and healthy volunteers","volume":"48","author":"Shinfuku","year":"2018","journal-title":"Am Journal of Nephrol"},{"issue":"3","key":"10.1016\/j.lfs.2024.122641_bb0110","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1124\/jpet.119.258731","article-title":"TP0463518, a novel prolyl hydroxylase inhibitor, specifically induces erythropoietin production in the liver","volume":"371","author":"Kato","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"15","key":"10.1016\/j.lfs.2024.122641_bb0115","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1182\/bloodadvances.2023009798","article-title":"Drugs activating hypoxia-inducible factors correct erythropoiesis and hepcidin levels via renal EPO induction in mice","volume":"7","author":"Nakai","year":"2023","journal-title":"Blood Adv."},{"issue":"5","key":"10.1016\/j.lfs.2024.122641_bb0120","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1172\/JCI38499","article-title":"HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice","volume":"119","author":"Mastrogiannaki","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.lfs.2024.122641_bb0125","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1053\/j.gastro.2011.03.007","article-title":"Hypoxia-inducible factor-2\u03b1 mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice","volume":"140","author":"Taylor","year":"2011","journal-title":"Gastroenterology"},{"issue":"5704","key":"10.1016\/j.lfs.2024.122641_bb0130","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1126\/science.1104742","article-title":"Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization","volume":"306","author":"Nemeth","year":"2004","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.lfs.2024.122641_bb0135","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bbamcr.2012.01.014","article-title":"Hepcidin and iron homeostasis","volume":"1823","author":"Ganz","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"7","key":"10.1016\/j.lfs.2024.122641_bb0140","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/ng.2996","article-title":"Identification of erythroferrone as an erythroid regulator of iron metabolism","volume":"46","author":"Kautz","year":"2014","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.lfs.2024.122641_bb0145","first-page":"1","article-title":"Updates on hypoxia-inducible factor prolyl hydroxylase inhibitors in the treatment of renal anemia","volume":"9","author":"Li","year":"2022","journal-title":"Kidney Dis (Basel)"},{"key":"10.1016\/j.lfs.2024.122641_bb0150","doi-asserted-by":"crossref","first-page":"114939","DOI":"10.1016\/j.bcp.2022.114939","article-title":"Esterification promotes the intracellular accumulation of roxadustat, an activator of hypoxia-inducible factors, to extend its effective duration","volume":"197","author":"Nakai","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"5","key":"10.1016\/j.lfs.2024.122641_bb0155","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.kint.2018.06.028","article-title":"Iron attenuates erythropoietin production by decreasing hypoxia-inducible transcription factor 2\u03b1 concentrations in renal interstitial fibroblasts","volume":"94","author":"Suzuki","year":"2018","journal-title":"Kidney Int."},{"issue":"8","key":"10.1016\/j.lfs.2024.122641_bb0160","doi-asserted-by":"crossref","first-page":"e0160555","DOI":"10.1371\/journal.pone.0160555","article-title":"Establishment of protocols for global metabolomics by LC-MS for biomarker discovery","volume":"11","author":"Saigusa","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.lfs.2024.122641_bb0165","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jphs.2020.09.004","article-title":"Effects of post-renal anemia treatment with the HIF-PHD inhibitor molidustat on adenine-induced renal anemia and kidney disease in mice","volume":"144","author":"Li","year":"2020","journal-title":"J. Pharmacol. Sci."},{"issue":"12","key":"10.1016\/j.lfs.2024.122641_bb0170","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1681\/ASN.2010010116","article-title":"Inhibition of prolyl hydroxylases increases erythropoietin production in ESRD","volume":"21","author":"Bernhardt","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.lfs.2024.122641_bb0175","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1038\/ncomms2950","article-title":"A mouse model of adult-onset anaemia due to erythropoietin deficiency","volume":"4","author":"Yamazaki","year":"2013","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.lfs.2024.122641_bb0180","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1172\/JCI122359","article-title":"Hepatic hepcidin\/intestinal HIF-2\u03b1 axis maintains iron absorption during iron deficiency and overload","volume":"129","author":"Schwartz","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.lfs.2024.122641_bb0185","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/dta.3188","article-title":"In vitro studies of hypoxia inducible factor-prolyl hydroxylase inhibitors daprodustat, desidustat, and vadadustat for equine doping control","volume":"14","author":"Philip","year":"2022","journal-title":"Drug Test Anal."},{"issue":"18","key":"10.1016\/j.lfs.2024.122641_bb0190","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1128\/MCB.05463-11","article-title":"Specific contribution of the erythropoietin gene 3\u2032 enhancer to hepatic erythropoiesis after late embryonic stages","volume":"31","author":"Suzuki","year":"2011","journal-title":"Mol. Cell. Biol."},{"issue":"3","key":"10.1016\/j.lfs.2024.122641_bb0195","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/bcpt.13538","article-title":"Drug-drug interaction of atazanavir on UGT1A1-mediated glucuronidation of molidustat in human","volume":"128","author":"van der Mey","year":"2021","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"6","key":"10.1016\/j.lfs.2024.122641_bb0200","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3390\/genes13061096","article-title":"Comparative transcriptome analysis of organ-specific adaptive responses to hypoxia provides insights to human diseases","volume":"13","author":"Hung","year":"2022","journal-title":"Genes (Basel)"},{"issue":"12","key":"10.1016\/j.lfs.2024.122641_bb0205","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1172\/JCI63924","article-title":"Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis","volume":"122","author":"Liu","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.lfs.2024.122641_bb0210","doi-asserted-by":"crossref","first-page":"e7875","DOI":"10.1371\/journal.pone.0007875","article-title":"Evidence for a lack of a direct transcriptional suppression of the iron regulatory peptide hepcidin by hypoxia-inducible factors","volume":"4","author":"Volke","year":"2009","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.lfs.2024.122641_bb0215","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/jcpt.13385","article-title":"Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: a meta-analysis including 13,146 patients","volume":"46","author":"Chen","year":"2021","journal-title":"J Clinical Pharm Ther"},{"issue":"5","key":"10.1016\/j.lfs.2024.122641_bb0220","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1002\/cpdd.1090","article-title":"Pharmacokinetics of daprodustat and metabolites in individuals with normal and impaired hepatic function","volume":"11","author":"Mahar","year":"2022","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.lfs.2024.122641_bb0225","doi-asserted-by":"crossref","first-page":"122754","DOI":"10.1016\/j.jchromb.2021.122754","article-title":"A highly sensitive and selective UPLC-MS\/MS assay for the determination of enarodustat (JTZ-951) in human plasma","volume":"1176","author":"Pai","year":"2021","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"issue":"7","key":"10.1016\/j.lfs.2024.122641_bb0230","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1111\/bcp.13584","article-title":"First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia","volume":"84","author":"B\u00f6ttcher","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"8","key":"10.1016\/j.lfs.2024.122641_bb0235","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/cpdd.927","article-title":"Effect of moderate hepatic impairment on the pharmacokinetics of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor","volume":"10","author":"Chavan","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"6","key":"10.1016\/j.lfs.2024.122641_bb0240","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.dmpk.2015.08.004","article-title":"Pharmacokinetics, pharmacodynamics and safety of single, oral doses of GSK1278863, a novel HIF-prolyl hydroxylase inhibitor, in healthy Japanese and Caucasian subjects","volume":"30","author":"Hara","year":"2015","journal-title":"Drug Metab. Pharmacokinet."},{"issue":"8","key":"10.1016\/j.lfs.2024.122641_bb0245","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cpdd.933","article-title":"Thorough QT\/QTc evaluation of the cardiac safety of enarodustat (JTZ-951), an oral erythropoiesis-stimulating agent, in healthy adults","volume":"10","author":"Pai","year":"2021","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"8","key":"10.1016\/j.lfs.2024.122641_bb0250","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1016\/j.clinthera.2021.06.013","article-title":"In vitro and clinical pharmacokinetic studies of the effects of iron-containing agents on vadadustat, an oral hypoxia-inducible factor-prolyl hydroxylase inhibitor","volume":"43","author":"Kokado","year":"2021","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.lfs.2024.122641_bb0255","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.clinthera.2021.03.025","article-title":"Effect of the phosphate binders sevelamer carbonate and calcium acetate on the pharmacokinetics of roxadustat after concomitant or time-separated administration in healthy individuals","volume":"43","author":"Groenendaal-van de Meent","year":"2021","journal-title":"Clin. Ther."},{"issue":"3","key":"10.1016\/j.lfs.2024.122641_bb0260","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/cpdd.597","article-title":"Evaluation of food and spherical carbon adsorbent effects on the pharmacokinetics of roxadustat in healthy nonelderly adult male Japanese subjects","volume":"8","author":"Shibata","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"10.1016\/j.lfs.2024.122641_bb0265","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40262-021-01095-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of roxadustat","volume":"61","author":"Czock","year":"2022","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.lfs.2024.122641_bb0270","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1124\/jpet.117.242503","article-title":"Discovery and preclinical characterization of GSK1278863 (daprodustat), a small molecule hypoxia inducible factor-prolyl hydroxylase inhibitor for anemia","volume":"363","author":"Ariazi","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2024.122641_bb0275","doi-asserted-by":"crossref","first-page":"172532","DOI":"10.1016\/j.ejphar.2019.172532","article-title":"JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-\u03b1 protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor","volume":"859","author":"Fukui","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"11","key":"10.1016\/j.lfs.2024.122641_bb0280","doi-asserted-by":"crossref","first-page":"e111838","DOI":"10.1371\/journal.pone.0111838","article-title":"Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects","volume":"9","author":"Flamme","year":"2014","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.lfs.2024.122641_bb0285","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1124\/jpet.122.001126","article-title":"Preclinical characterization of Vadadustat (AKB-6548), an oral small molecule hypoxia-inducible factor prolyl-4-hydroxylase inhibitor, for the potential treatment of renal anemia","volume":"383","author":"Zuk","year":"2022","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.lfs.2024.122641_bb0290","author":"World Anti-Doping Agency"},{"issue":"5","key":"10.1016\/j.lfs.2024.122641_bb0295","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.jhep.2007.12.021","article-title":"2-Oxoglutarate-dependent oxygenases control hepcidin gene expression","volume":"48","author":"Braliou","year":"2008","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.lfs.2024.122641_bb0300","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.kint.2021.04.030","article-title":"Novel roles of HIF-PHIs in chronic kidney disease: the link between iron metabolism, kidney function, and FGF23","volume":"100","author":"Ikeda","year":"2021","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.lfs.2024.122641_bb0305","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000504850","article-title":"Treatment of renal anemia with roxadustat: advantages and achievement","volume":"6","author":"Li","year":"2020","journal-title":"Kidney Dis (Basel)"},{"key":"10.1016\/j.lfs.2024.122641_bb0310","doi-asserted-by":"crossref","first-page":"105020","DOI":"10.1016\/j.phrs.2020.105020","article-title":"Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: a network meta-analysis","volume":"159","author":"Zheng","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.lfs.2024.122641_bb0315","doi-asserted-by":"crossref","DOI":"10.3164\/jcbn.24-8","article-title":"Crosstalk between oxygen signaling and iron metabolism in renal interstitial fibroblasts","author":"Suzuki","year":"2024","journal-title":"J. Clin. Biochem. Nutr."}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524002315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320524002315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T18:10:41Z","timestamp":1726855841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320524002315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":63,"alternative-id":["S0024320524002315"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2024.122641","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2024.122641","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"122641"}}